The Conversation (0)
The company has announced that its EGRIFTA SV treatment is now commercially available in the United States.
Theratechnologies (TSX:TH, NASDAQ:THTX) has announced that EGRIFTA SV is now commercially available in the US.
As quoted in the press release:
Our salesforce has started detailing the product to physicians today while the supply chain is being filled, and people living with HIV and lipodystrophy will have access to a new formulation of tesamorelin for the reduction of hard belly (excess hard abdominal fat) in the next few days. Lipodystrophy is a serious metabolic condition which is associated with the development of insulin resistance, diabetes, fatty liver and high triglyceride levels.
EGRIFTA SVᵀᴹ is a growth hormone-releasing factor analog. EGRIFTA SVᵀᴹ is a once-daily small volume subcutaneous injection that is presented in a single vial and stored at room temperature.
“Given its many improvements over the original version of tesamorelin, EGRIFTA SVᵀᴹ should help sustain growth for tesamorelin over the coming years. We are committed to continue managing the lifecycle of our products in order to help people living with HIV,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc.